KEYNOTE-407
KEYNOTE-407 showed that adding pembrolizumab to chemotherapy helped people with squamous lung cancer live longer whatever their PD-L1 level, and made chemo-immunotherapy the standard first treatment for this type.
Overview
KEYNOTE-407 randomised 559 patients with untreated metastatic squamous non-small-cell lung cancer to carboplatin and either paclitaxel or nab-paclitaxel with pembrolizumab or with placebo, followed by pembrolizumab or placebo maintenance. Squamous tumours had been left behind by the targeted-therapy era and had no chemotherapy-free option beyond high-PD-L1 pembrolizumab.
Both primary endpoints, overall survival and progression-free survival, favoured the pembrolizumab arm, and the benefit was seen across PD-L1 expression groups. The combination was approved in the United States in October 2018 and became the first-line standard for squamous disease without a driver mutation.
Similar pages
not linked directly; found by shared links- TrialCheckMate 227
Shares Lung cancer (all types), PD-L1-high non-small-cell lung cancer without a driver mutation, Non-small-cell lung cancer and the tag subtype-trials.
- TrialPACIFIC-2
Shares Lung cancer (all types), Carboplatin, Non-small-cell lung cancer and the tag subtype-trials.
- TrialCHRYSALIS
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialDESTINY-Lung01
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
- TrialKEYNOTE-412
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialKEYNOTE-057
Shares Merck & Co. (MSD), Pembrolizumab and the tag subtype-trials.
- TrialBrighTNess
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-trials.
- TrialESOPEC
Shares Paclitaxel / nab-paclitaxel, Carboplatin and the tag subtype-trials.